Clinical Trial Update: Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 300 mg vs 150 mg secukinumab after escalation to 300 mg in Ankylosing Spondylitis; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ankylosing Spondylitis | Phase 4 | Status: COMPLETED | Results posted: 2022-04-08